| 李 力,徐 照,吴春叶,赵晶晶,吉康生.风湿祛痛胶囊联合塞来昔布胶囊治疗强直性脊柱炎的疗效及对血液流变学和血清炎性因子的影响[J].现代生物医学进展英文版,2023,(16):3093-3096. |
| 风湿祛痛胶囊联合塞来昔布胶囊治疗强直性脊柱炎的疗效及对血液流变学和血清炎性因子的影响 |
| Effect of Fengshi Qutong Capsule Combined with Celecoxib Capsule in the Treatment of Ankylosing Spondylitis and its Influence on Hemorheology and Serum Inflammatory Factors |
| Received:February 23, 2023 Revised:March 18, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.16.018 |
| 中文关键词: 风湿祛痛胶囊 塞来昔布胶囊 强直性脊柱炎 疗效 血液流变学 炎性因子 |
| 英文关键词: Fengshi Qutong capsule Celecoxib capsule Ankylosing spondylitis Efficacy Hemorheology Inflammatory factors |
| 基金项目:天津市卫生和计划生育委员会科技基金项目（2015KZ004） |
|
| Hits: 739 |
| Download times: 378 |
| 中文摘要: |
| 摘要 目的：探讨强直性脊柱炎（AS）患者经风湿祛痛胶囊联合塞来昔布胶囊治疗后的疗效及对血液流变学和血清炎性因子的影响。方法：选取2014年8月-2021年12月在联勤保障部队第九八三医院治疗的80例AS患者。按照随机数字表法分为对照组（常规治疗及塞来昔布胶囊治疗，40例）和研究组（常规治疗及风湿祛痛胶囊联合塞来昔布胶囊治疗，40例），两组患者均治疗8周。对比两组血液流变学指标、血清炎性因子指标、视觉模拟评分法（VAS）评分、C反应蛋白（CRP）、巴氏强直性脊柱炎疾病活动指数（BASDAI）评分、红细胞沉降率（ESR），同时记录两组治疗期间不良反应发生情况。结果：研究组治疗8周后BASDAI、VAS评分低于对照组（P<0.05）。研究组治疗8周后CRP、ESR低于对照组（P<0.05）。研究组治疗8周后全血高切黏度、血浆黏度、全血低切黏度、红细胞压积低于对照组（P<0.05）。研究组治疗8周后白介素-23（IL-23）、肿瘤坏死因子-α（TNF-α）、白介素-1β（IL-1β）均低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：风湿祛痛胶囊联合塞来昔布胶囊治疗AS，可有效缓解患者的临床症状，抑制疾病进展，可能与调节血液流变学、降低炎性因子水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Fengshi Qutong capsule combined with celecoxib capsule in the treatment of ankylosing spondylitis (AS) and its influence on hemorheology and serum inflammatory factors. Methods: 80 patients with AS who were treated in The 983 Hospital of the Joint Service Support Force from August 2014 to December 2021 were selected as the research objects. According to the method of random number table, they were divided into control group (40 cases treated with conventional therapy and celecoxib capsule) and study group (40 cases treated with conventional therapy and Fengshi Qutong capsule combined with celecoxib capsule). Both groups were treated for 8 weeks. The hemorheology indexes, serum inflammatory factors indexes, visual analogue scale (VAS) score, C-reactive protein (CRP), Bath ankylosing spondylitis disease activity index (PASDAI) score and erythrocyte sedimentation rate (ESR) were compared in the two groups, and the adverse reactions during treatment in the two groups were recorded. Results: After 8 weeks of treatment, BASDAI and VAS scores in the study group were lower than those in the control group (P<0.05). After 8 weeks of treatment, CRP and ESR in the study group were lower than those in the control group(P<0.05). After 8 weeks of treatment, the whole blood high shear viscosity, plasma viscosity, whole blood low shear viscosity and hematocrit in the study group were lower than those in the control group (P<0.05). Interleukin-23 (IL-23), tumor necrosis factor-α (TNF-α)and Interleukin-1 β (IL-1 β) in the study group after 8 weeks of treatment were lower than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The combination of Fengshi Qutong capsule and celecoxib capsule can effectively relieve the clinical symptoms of patients with AS and prevent the progression of the disease, which may be related to regulating hemorheology and reducing the level of inflammatory factors. |
|
View Full Text
View/Add Comment Download reader |
| Close |
